Novartis bets $80M on Pliant’s preclinical NASH prospect

October 23, 2019

As reported by FierceBiotech on October 23, 2019.

Novartis has put up an initial $80 million to land the global license to Pliant Therapeutics’ preclinical nonalcoholic steatohepatitis (NASH) asset and three additional candidates. The NASH drug, PLN-1474, is a small molecule inhibitor of integrin α_Vβ₁ Pliant thinks can reduce the growth of fibrotic tissue in the liver.

Full news article here.